Erik Wilhelm Schrumpf

• Valestrand, Laura Cecilie; Berntsen, Natalie Lie; Fei, Zheng; Schrumpf, Erik; Hansen, Simen Hyll & Karlsen, Tom Hemming [Show all 10 contributors for this article] (2020). Lipid antigens in bile from patients with chronic liver diseases activate natural killer T cells. Clinical and Experimental Immunology. ISSN 0009-9104. doi: 10.1111/cei.13541. Full text in Research Archive
• Zenouzi, Roman; Liwinski, T; Yamamura, J; Weiler-Normann, Christina; Sebode, Marcial & Keller, S [Show all 50 contributors for this article] (2018). Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret. Alimentary Pharmacology and Therapeutics. ISSN 0269-2813. 48(2), p. 169–178. doi: 10.1111/apt.14797.
• Berntsen, Natalie Lie; Fosby, Bjarte; Tan, Corey; Reims, Henrik Mikael; Øgaard, Jonas & Jiang, Xiaojun [Show all 12 contributors for this article] (2018). Natural killer T cells mediate inflammation in the bile ducts. Mucosal Immunology. ISSN 1933-0219. p. 1–9. doi: 10.1038/s41385-018-0066-8.
• Alberts, R; de Vries, EMG; Goode, EC; Jiang, Xiaojun; Sampaziotis, Fotios & Rombouts, K [Show all 50 contributors for this article] (2017). Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut. ISSN 0017-5749. 67(8), p. 1517–1524. doi: 10.1136/gutjnl-2016-313598.
• Fickert, Peter; Hirschfield, Gideon M.; Denk, Gerald; Marschall, Hanns-Ulrich; Altorjay, Istvan & Färkkilä, Martti [Show all 20 contributors for this article] (2017). norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. Journal of Hepatology. ISSN 0168-8278. 67(3), p. 549–558. doi: 10.1016/j.jhep.2017.05.009.
• Vesterhus, Mette; Holm, Anders; Hov, Johannes Espolin Roksund; Nygård, Ståle; Schrumpf, Erik & Melum, Espen [Show all 23 contributors for this article] (2017). Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. Journal of Hepatology. ISSN 0168-8278. 66(6), p. 1214–1222. doi: 10.1016/j.jhep.2017.01.019.
• Hov, Johannes Espolin Roksund; Boberg, Kirsten Muri; Taraldsrud, Eli; Vesterhus, Mette; Boyadzhieva, Maria & Solberg, Inger Camilla [Show all 11 contributors for this article] (2017). Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis. Liver international (Print). ISSN 1478-3223. 37(3), p. 458–465. doi: 10.1111/liv.13238.
• Kummen, Martin; Holm, Kristian; Anmarkrud, Jarl Andreas; Nygård, Ståle; Vesterhus, Mette & Høivik, Marte [Show all 14 contributors for this article] (2016). The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut. ISSN 0017-5749. 66(4), p. 611–619. doi: 10.1136/gutjnl-2015-310500. Show summary

  Objective: Gut microbiota could influence gut, as well as hepatic and biliary immune responses. We therefore thoroughly characterised the gut microbiota in primary sclerosing cholangitis (PSC) compared with healthy controls (HC) and patients with ulcerative colitis without liver disease. Design: We prospectively collected 543 stool samples. After a stringent exclusion process, bacterial DNA was submitted for 16S rRNA gene sequencing. PSC and HC were randomised to an exploration panel or a validation panel, and only significant results (p<0.05, QFDR<0.20) in both panels were reported, followed by a combined comparison of all samples against UC. Results: Patients with PSC (N=85) had markedly reduced bacterial diversity compared with HC (N=263, p<0.0001), and a different global microbial composition compared with both HC (p<0.001) and UC (N=36, p<0.01). The microbiota of patients with PSC with and without IBD was similar. Twelve genera separated PSC and HC, out of which 11 were reduced in PSC. However, the Veillonella genus showed a marked increase in PSC compared with both HC (p<0.0001) and UC (p<0.02). Using receiver operating characteristic analysis, Veillonella abundance yielded an area under the curve (AUC) of 0.64 to discriminate PSC from HC, while a combination of PSC- associated genera yielded an AUC of 0.78. Conclusions: Patients with PSC exhibited a gut microbial signature distinct from both HC and UC without liver disease, but similar in PSC with and without IBD. The Veillonella genus, which is also associated with other chronic inflammatory and fibrotic conditions, was enriched in PSC.

• Ponsioen, Cyriel Y.; Chapman, Roger W.; Chazouilleres, Olivier; Hirschfield, Gideon M.; Karlsen, Tom Hemming & Lohse, Ansgar W. [Show all 10 contributors for this article] (2016). Surrogate endpoints for clinical trials in primary sclerosing Cholangitis; review and results from an international PSC study Group consensus process. Hepatology. ISSN 0270-9139. 63(4), p. 1357–1367. doi: 10.1002/hep.28256.
• Andersen, Ina Marie; Fosby, Bjarte; Boberg, Kirsten Muri; Clausen, Ole Petter Fraas; Jebsen, Peter Wilhelm & Melum, Espen [Show all 10 contributors for this article] (2015). Indications and Outcomes in Liver Transplantation in Patients with Primary Sclerosing Cholangitis in Norway. Transplantation direct. ISSN 2373-8731. 1(9). doi: 10.1097/TXD.0000000000000548.
• Vesterhus, Mette; Hov, Johannes Espolin Roksund; Holm, Anders; Schrumpf, Erik; Nygård, Ståle & Godang, Kristin [Show all 25 contributors for this article] (2015). Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology. ISSN 0270-9139. 62(1), p. 188–197. doi: 10.1002/hep.27825.
• Fosby, Bjarte; Melum, Espen; Bjøro, Kristian; Bennet, William; Rasmussen, Allan & Andersen, Ina Riise [Show all 30 contributors for this article] (2015). Liver transplantation in the Nordic countries-An intention to treat and post-transplant analysis from the Nordic Liver Transplant Registry 1982-2013. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 50(6), p. 797–808. doi: 10.3109/00365521.2015.1036359.
• Andresen, Kim; Boberg, Kirsten Muri; Vedeld, Hege Marie; Honne, Hilde; Jebsen, Peter Wilhelm & Hektoen, Merete [Show all 16 contributors for this article] (2015). Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma. Hepatology. ISSN 0270-9139. 61(5), p. 1651–1659. doi: 10.1002/hep.27707.
• Schrumpf, Erik; Boberg, Kirsten Muri & Karlsen, Tom Hemming (2015). Primary sclerosing cholangitis-the Norwegian experience. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 50(6), p. 781–796. doi: 10.3109/00365521.2015.1028996.
• Næss, Sigrid; Lie, Benedicte Alexandra; Melum, Espen; Olsson, Marita; Hov, Johannes Espolin Roksund & Croucher, PJP [Show all 15 contributors for this article] (2014). Refinement of the MHC risk map in a Scandinavian primary sclerosing cholangitis population. PLOS ONE. ISSN 1932-6203. 9:e0114486(12). doi: 10.1371/journal.pone.0114486.
• Næss, Sigrid; Björnsson, Einar; Anmarkrud, Jarl Andreas; Al Mamari, Said; Juran, Brian D. & Lazaridis, Konstantinos N. [Show all 15 contributors for this article] (2014). Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. Liver international (Print). ISSN 1478-3223. 34(10), p. 1488–1495. doi: 10.1111/liv.12492.
• Kummen, Martin; Schrumpf, Erik & Boberg, Kirsten Muri (2013). Liver abnormalities in bowel diseases. Baillière's Best Practice & Research : Clinical Gastroenterology. ISSN 1521-6918. 27(4), p. 531–542. doi: 10.1016/j.bpg.2013.06.013. Show summary

  Liver abnormalities are often seen in bowel diseases. Whether these represent aspects of two separate diseases, or if one is causing the other, is not always easy to decide. Extraintestinal manifestations of inflammatory bowel disease (IBD) or coeliac disease are frequently observed. Of these extraintestinal manifestations, hepatic disorders are among the most common. Primary sclerosing cholangitis (PSC) and primary biliary cirrhosis are the most frequent hepatic disorders in IBD and coeliac disease, respectively. Genetic studies have lately elucidated the associations between IBD and PSC, but there is still a long way until we have complete understanding of the molecular aetiology and pathophysiology of these conditions. There is no curative treatment available for PSC, besides liver transplantation. Steatosis and cholelithiasis are also common in IBD, as are signs of hepatic injury due to IBD treatment. Less common liver abnormalities include liver abscesses, hepatic thromboembolic events, granulomatous liver disease and hepatic amyloidosis.

• Liu, Jimmy Z.; Hov, Johannes Espolin Roksund; Folseraas, Trine; Ellinghaus, E; Rushbrook, SM & Doncheva, NT [Show all 84 contributors for this article] (2013). Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics. ISSN 1061-4036. 45(6), p. 670–675. doi: 10.1038/ng.2616.
• Jørgensen, Kristin Kaasen; Lindstrøm, Lina; Småstuen, Milada Cvancarova; Karlsen, Tom Hemming; Castedal, Maria & Friman, Styrbjörn [Show all 15 contributors for this article] (2013). Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease. Clinical Gastroenterology and Hepatology. ISSN 1542-3565. 11(5), p. 517–523. doi: 10.1016/j.cgh.2012.12.027.
• Ellinghaus, David; Folseraas, Trine; Holm, Kristian; Ellinghaus, Eva; Melum, Espen & Balschun, Tobias [Show all 37 contributors for this article] (2013). Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology. ISSN 0270-9139. 58(3), p. 1074–1083. doi: 10.1002/hep.25977.
• Andresen, Kim; Boberg, Kirsten Muri; Vedeld, Hege Marie; Honne, Hilde; Hektoen, Merete & Wadsworth, Christopher A [Show all 13 contributors for this article] (2012). Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. Epigenetics. ISSN 1559-2294. 7(11), p. 1249–1257. doi: 10.4161/epi.22191.
• Folseraas, Trine; Melum, Espen; Rausch, Philipp; Juran, Brian D.; Ellinghaus, Eva & Shiryaev, Alexey [Show all 40 contributors for this article] (2012). Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. Journal of Hepatology. ISSN 0168-8278. 57(2), p. 366–375. doi: 10.1016/j.jhep.2012.03.031.
• Jørgensen, Kristin Kaasen; Lindstrom, Lina; Cvancarova, Milada; Castedal, Maria; Friman, Styrbjörn & Schrumpf, Erik [Show all 14 contributors for this article] (2012). Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 47(8-9), p. 1021–1029. doi: 10.3109/00365521.2012.685754.
• Jørgensen, Kristin Kaasen; Grzyb, Krzysztof; Lundin, Knut E A; Clausen, Ole Petter Fraas; Aamodt, Geir & Schrumpf, Erik [Show all 8 contributors for this article] (2012). Inflammatory bowel disease in patients with primary sclerosing cholangitis: clinical characterization in liver transplanted and non transplanted pateints. Inflammatory Bowel Diseases. ISSN 1078-0998. 18(3), p. 536–545. doi: 10.1002/ibd.21699.
• Hov, Johannes Espolin Roksund; Keitel, Verena; Schrumpf, Erik; Häussinger, Dieter & Karlsen, Tom Hemming (2011). TGR5 Sequence Variation in Primary Sclerosing Cholangitis. Digestive Diseases. ISSN 0257-2753. 29(1), p. 78–84. doi: 10.1159/000324138.
• Melum, Espen; Franke, Andre; Schramm, Christoph; Weismüller, Tobias J.; Gotthardt, Daniel & Offner, Felix A. [Show all 43 contributors for this article] (2011). Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nature Genetics. ISSN 1061-4036. 43(1), p. 17–19. doi: 10.1038/ng.728.
• Boberg, Kirsten Muri; Chapman, Roger W.; Hirschfield, Gideon M.; Lohse, Ansgar W.; Manns, Michael P. & Schrumpf, Erik (2011). Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. Journal of Hepatology. ISSN 0168-8278. 54(2), p. 374–385. doi: 10.1016/j.jhep.2010.09.002.
• Hov, Johannes Espolin Roksund; Kosmoliaptsis, Vasilis; Traherne, James A.; Olsson, Marita; Boberg, Kirsten Muri & Bergquist, Annika [Show all 12 contributors for this article] (2011). Electrostatic Modifications of the Human Leukocyte Antigen-DR P9 Peptide-Binding Pocket and Susceptibility to Primary Sclerosing Cholangitis. Hepatology. ISSN 0270-9139. 53(6), p. 1967–1976. doi: 10.1002/hep.24299.
• Karlsen, Tom Hemming; Schrumpf, Erik & Boberg, Kirsten Muri (2010). Primary sclerosing cholangitis. Baillière's Best Practice & Research : Clinical Gastroenterology. ISSN 1521-6918. 24(5), p. 655–666. doi: 10.1016/j.bpg.2010.07.005.
• Karlsen, Tom Hemming; Schrumpf, Erik & Boberg, Kirsten Muri (2010). Update on primary sclerosing cholangitis. Digestive and Liver Disease. ISSN 1590-8658. 42(6), p. 390–400. doi: 10.1016/j.dld.2010.01.011.
• Hov, Johannes Espolin Roksund; Keitel, V; Lærdahl, Jon Kristen; Spomer, L; Ellinghaus, E & ElSharawy, A [Show all 36 contributors for this article] (2010). Mutational Characterization of the Bile Acid Receptor TGR5 in Primary Sclerosing Cholangitis. PLOS ONE. ISSN 1932-6203. 5(8). doi: 10.1371/journal.pone.0012403.
• Ponsioen, Cyriel Y.; Reitsma, JB; Boberg, Kirsten Muri; Aabakken, Lars; Rauws, Erik & Schrumpf, Erik (2010). Validation of a cholangiographic prognostic model in primary sclerosing cholangitis. Endoscopy. ISSN 0013-726X. 42(9), p. 742–747. doi: 10.1055/s-0030-1255527.
• Karlsen, Tom Hemming; Franke, Andre; Melum, Espen; Kaser, Arthur; Hov, Johannes Espolin Roksund & Balschun, Tobias [Show all 32 contributors for this article] (2010). Genome-Wide Association Analysis in Primary Sclerosing Cholangitis. Gastroenterology. ISSN 0016-5085. 138(3), p. 1102–1111. doi: 10.1053/j.gastro.2009.11.046.
• Scholz, Tim; Karlsen, Tom Hemming; Sanengen, Truls; Schrumpf, Erik & Foss, Aksel (2009). Levertransplantasjon i Norge gjennom 25 år. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 129(24), p. 2587–2592.
• Forsbring, Monika; Vik, Erik Sebastian; Dalhus, Bjørn; Karlsen, Tom Hemming; Bergquist, A. & Schrumpf, Erik [Show all 9 contributors for this article] (2009). Catalytically impaired hMYH and NEIL1 mutant proteins identified in patients with primary sclerosing cholangitis and cholangiocarcinoma. Carcinogenesis. ISSN 0143-3334. 30(7), p. 1147–1154. doi: 10.1093/carcin/bgp118.
• Melum, Espen; Karlsen, TH; Schrumpf, Erik; Bergquist, A; Thorsby, Erik & Boberg, Kirsten Muri [Show all 7 contributors for this article] (2008). Cholanglocarcinoma in primary sclerosing cholangitis is associated with NKG2D Polymorphisms. Hepatology. ISSN 0270-9139. 47, p. 90–96. doi: 10.1002/hep.21964.
• Wiencke, Kristine; Karlsen, Hemming Tom; Boberg, Kirsten Muri; Thorsby, Erik; Schrumpf, Erik & Lie, Benedicte Alexandra [Show all 7 contributors for this article] (2007). Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes. Tissue Antigens. ISSN 0001-2815. 69, p. 161–169. doi: 10.1111/j.1399-0039.2006.00738.x.
• Karlsen, Hemming Tom; Boberg, Kirsten Muri; Vatn, Morten H; Bergquist, A; Hampe, J & Schrumpf, Erik [Show all 9 contributors for this article] (2007). Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis. Genes and Immunity. ISSN 1466-4879. 8. doi: 10.1038/sj.gene.6364377.
• Karlsen, Hemming Tom; Boberg, Kirsten Muri; Olsson, M; Sun, JY; Senitzer, D & Bergquist, A [Show all 9 contributors for this article] (2007). Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. Journal of Hepatology. ISSN 0168-8278. 46. doi: 10.1016/j.jhep.2007.01.032.
• Wiencke, Kristine; Boberg, Kirsten Muri; Donaldson, P; Harbo, Hanne Flinstad; Ling, V & Schrumpf, Erik [Show all 7 contributors for this article] (2006). No major effect of the CD28/CTLA4/ICOS gene region on susceptibility to primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 41.
• Boberg, Kirsten Muri; Jebsen, Peter Wilhelm; Clausen, Ole Petter Fraas; Foss, Aksel; Aabakken, Lars & Schrumpf, Erik (2006). Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. Journal of Hepatology. ISSN 0168-8278. 45, p. 568–574.
• Berstad, Audun Elnæs; Aabakken, Lars; Smith, Hans-Jørgen; Aasen, Steinar; Boberg, Kirsten Muri & Schrumpf, Erik (2006). Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clinical Gastroenterology and Hepatology. ISSN 1542-3565. 4(4), p. 514–520.
• Bowlus, Christopher L.; Karlsen, Tom Hemming; Broomé, Ulrika; Thorsby, Erik; Vatn, Morten & the, IBSEN study group [Show all 9 contributors for this article] (2006). Analysis of MAdCAM-1 and ICAM-1 polymorphisms in 365 Scandinavian patients with primary sclerosing cholangitis. Journal of Hepatology. ISSN 0168-8278. 45(5), p. 704–710.
• Brandsæter, Bjørn Jardar; Schrumpf, Erik; Bentdal, Øystein H.; Braband, Knut; Smith, Hans-Jørgen & Abildgaard, Andreas [Show all 8 contributors for this article] (2005). Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver transplantation. ISSN 1527-6465. 11(11), p. 1361–1369.
• Bjøro, K & Schrumpf, Erik (2004). Liver transplantation for primary sclerosing cholangitis (Invited review). Journal of Hepatology. ISSN 0168-8278. 40, p. 570–577.
• Boberg, KM & Schrumpf, Erik (2004). Diagnosis and treatment of cholangiocarcinoma. Current Gastroenterology Reports. ISSN 1522-8037. 6, p. 52–59.
• Wiencke, Kristine; Louka, Andrew ; Spurkland, Anne; Vatn, Morten H; Schrumpf, Erik & Boberg, Kirsten Muri (2004). Association of matrix metalloproteinase-1 and-3 promoter polymorphisms with clinical subsets of Norwegian primary sclerosing cholangitis patients. Journal of Hepatology. ISSN 0168-8278. 41, p. 209–214.
• Brandsæter, Bjørn Jardar; Schrumpf, Erik; Clausen, Ole Petter Fraas; Abildgaard, Andreas; Hafsahl, Geir & Bjøro, Kristian (2004). Recurrent sclerosing cholangitis or ischemic bile duct lesions - a diagnostic challenge? Liver transplantation. ISSN 1527-6465. 10(8), p. 1073–1074.
• Brandsæter, Bjørn Jardar; Isoniemi, H; Broome, U; Olausson, M; Backman, L & Hansen, B [Show all 14 contributors for this article] (2004). &quot;Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy&quot;. Journal of Hepatology. ISSN 0168-8278. 40, p. 815–822.
• Schrumpf, Erik & Boberg, Kirsten Muri (2003). Hepatic and extrahepatic malignancies and primary sclerosing cholangitis. Gut. ISSN 0017-5749. 52.
• Bjøro, Kristian; Brandsæter, Bjørn Jardar; Wiencke, Kristine; Bjøro, Trine; Godang, Kristin & Bollerslev, Jens [Show all 7 contributors for this article] (2003). Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 38, p. 320–327.
• Boberg, Kirsten Muri; Jebsen, Peter W.; Clausen, Ole Petter Fraas; Aabakken, Lars; Brekke, Inge Bjørn & Schrumpf, Erik (2003). Cholangiocarcinoma in situ in primary sclerosing cholangitis: diagnosis by brush cytology and treatment by liver transplantation. Journal of Hepatology. ISSN 0168-8278. 39.
• Boberg, Kirsten Muri; Egeland, Thore & Schrumpf, Erik (2003). Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 38, p. 991–995.
• Brandsæter, Bjørn Jardar; Frimann, S.; Broome, U.; Isoniemi, H.; Olausson, M & Backman, L [Show all 14 contributors for this article] (2003). Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 38, p. 1176–1183.
• Brandsæter, Bjørn Jardar; Broome, U.; Isoniemi, H.; Frimann, S.; Hansen, B. & Schrumpf, Erik [Show all 14 contributors for this article] (2003). Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. Liver transplantation. ISSN 1527-6465. 9, p. 961–969.
• Boberg, Kirsten Muri; Rocca, G.; Egeland, Thore; Bergquist, A.; Broome, U. & Caballeria, L. [Show all 12 contributors for this article] (2002). Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology 2002; 35: 652-657. Hepatology. ISSN 0270-9139. 35, p. 652–57.
• Bjørnsson, E.; Boberg, Kirsten Muri; Cullen, S.; Fleming, K.A.; Clausen, Ole Petter Fraas & Fausa, Olav [Show all 8 contributors for this article] (2002). Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut. ISSN 0017-5749. 51, p. 731–735.
• Boberg, Kirsten Muri; Bergquist, A.; Mitchell, S.A.; Pares, A.; Rosina, F. & Broome, U. [Show all 11 contributors for this article] (2002). Cholangiocarcinoma in primary sclerosing cholangitis : risk factors and clinical presentation. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 37, p. 1205–1211.
• Schrumpf, Erik & Boberg, Kirsten Muri (2001). Epidemiology of primary sclerosing cholangitis, Best practice & Research Clinical gastroenterology. p. 553–562.
• Schrumpf, Erik; Søreide, Odd & Aabakken, Lars (2001). Editorial status 2001. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 36.
• Leidenius, M.; Höckerstedt, K.; Broome, U.; Ericzon, Bo-Göran; Frimann, S. & Olausson, M [Show all 7 contributors for this article] (2001). Hepatobiliary carcinoma in primary sclerosing cholangitis: a case control study. Journal of Hepatology. ISSN 0168-8278. 34, p. 792–798.
• Offstad, Jon; Schrumpf, Erik; Geiran, Odd; Søreide, Odd & Simonsen, Svein (2001). Plasma exchange and heart-liver transplantation in a patient with homozygous familial hypercholesterolemia. Clinical Transplantation. ISSN 0902-0063. 15, p. 432–436.
• Wiencke, Kristine; Spurkland, Anne; Schrumpf, Erik & Boberg, Kirsten Muri (2001). Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles. Hepatology. ISSN 0270-9139. 34, p. 625–630. Show summary

  Abstract: Susceptibility to primary sclerosing cholangitis (PSC) is associated with HLA-B8, -DR3, -DR2, and -DR6. It is not established whether these HLA genes or closely linked genes confer the primary disease susceptibility. MICA and MICB genes are found in the class I region between HLA-B and DRB. MICA is expressed in gastrointestinal epithelium and activates gammadelta T cells in the gut. Because PSC is strongly associated with inflammatory bowel disease, we investigated whether MICA and MICB contribute to the HLA-associated genetic susceptibility to develop PSC. The study included 130 PSC patients and 306 healthy controls, previously typed for HLA class I and II genes, typed for 5 MICA and 15 MICB microsatellite alleles. The phenotype frequencies of MICA5.1 and MICB24 were significantly increased among PSC patients compared with controls (90% vs. 74%; odds ratio [OR] = 3.2; P(c) = 3 x 10(-3) and 58% vs. 29%; OR = 3.3; P(c) < 1 x 10(-7), respectively). When stratified for B8- or DR3-positive and -negative individuals, the association of these markers to PSC was no longer evident. However, we observed that B8 and DR3 were associated to PSC only in the presence of both MICA5.1 and MICB24 markers. The frequency of individuals carrying all 4 alleles was significantly increased among the PSC patients compared with controls (49% vs. 18%; OR = 4.5; P(c) < 1 x 10(-7)). Our data indicate that PSC is associated to the extended B8-MICA5.1-MICB24-DR3 haplotype.

• Boberg, Kirsten Muri; Spurkland, Anne; Rocca, G.; Egeland, Thore; Saarinen, S. & Mitchell, S.A. [Show all 12 contributors for this article] (2001). The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 36(8), p. 886–890. Show summary

  Abstract: BACKGROUND: An improvement of prognostic models in primary sclerosing cholangitis (PSC) is needed. In particular, inclusion of prognostic markers that are independent of the disease stage would be advantageous. We investigated whether HLA class II genes associated with PSC are also related to disease progression. METHODS: The study included 265 PSC patients from five European countries with a median follow-up of 9.1 years. The end-points were death (n = 38) or liver transplantation (n = 52). Thirty patients developed cholangiocarcinoma during follow-up. RESULTS: The DRB1*03,DQA1*0501, DQB1*02 (i.e. DR3,DQ2) heterozygous genotype was associated with an increased risk of death or liver transplantation (hazard ratio = 1.63; 95% confidence interval (CI) =1.06-2.52). The presence of a DQ6 encoding haplotype (DQB1*0603 or DQB1*0602) in DR3,DQ2 negative individuals was associated with a reduced risk of death or liver ansplantation (hazard ratio = 0.57; 95% CI = 0.36-0.88). There was a trend towards an increased risk of developing cholangiocarcinoma among DR4,DQ8 positive patients, but this did not reach significance (odds ratio = 2.27; 95% CI = 0.78-6.62). CONCLUSION: The DR3,DQ2 heterozygous genotype is associated with a more rapid progression of PSC, whereas HLA-DQ6 is associated with a retarded disease progression. It is possible that the DR4,DQ8 haplotype is related to cholangiocarcinoma development.

• Mitchell, S.A.; Grove, J.; Spurkland, Anne; Boberg, Kirsten Muri; Fleming, K.A. & Day, C.P. [Show all 8 contributors for this article] (2001). Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut. ISSN 0017-5749. 49(2), p. 288–294. Show summary

  Abstract: BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown aetiology. Abnormalities in immune regulation and genetic associations suggest that PSC is an immune mediated disease. Several polymorphisms within the tumour necrosis factor alpha (TNF-alpha) and interleukin 10 (IL-10) promoter genes have been described which influence expression of these cytokines. This study examines the possible association between polymorphisms at the -308 and -627 positions in the TNF-alpha and IL-10 promoter genes, respectively, and susceptibility to PSC. METHODS: TNF-alpha -308 genotypes were studied by polymerase chain reaction (PCR) in 160 PSC patients from Norway and the UK compared with 145 ethnically matched controls. IL-10 -627 genotypes were studied by PCR in 90 PSC patients compared with 84 ethnically matched controls. RESULTS: A total of 16% of Norwegian PSC patients and 12% of British PSC patients were homozygous for the TNF2 allele compared with 3% and 6% of respective controls. The TNF2 allele was present in 60% of PSC patients versus 30% of controls (OR(combined data)=3.2 (95% confidence intervals (CI) 1.8--4.5); p(corr)=10(-5)). The association between the TNF2 allele and susceptibility to PSC was independent of the presence of concurrent inflammatory bowel disease (IBD) in the PSC patients; 61% of PSC patients without IBD had TNF2 compared with 30% of controls (OR(combined data)=3.2 (95% CI 1.2--9.0); p(corr)=0.006 ). There was no difference in the -627 IL-10 polymorphism distributions between patients and controls in either population. The increase in TNF2 allele in PSC patients only occurs in the presence of DRB1*0301 (DR3) and B8. In the combined population data, DRB1*0301 showed a stronger association with susceptibility to PSC than both the TNF2 and B8 alleles (OR(combined data)=3.8, p(corr)=10(-6) v OR(combined data)=3.2, p(corr)=10(-5) v OR(combined data )=3.41, p(corr)=10(-4), respectively). CONCLUSIONS: This study identified a significant association between possession of the TNF2 allele, a G-->A substitution at position -308 in the TNF-alpha promoter, and susceptibility to PSC. This association was secondary to the association of PSC with the A1-B8-DRB1*0301-DQA1*0501-DQB1*0201 haplotype. No association was found between the IL-10 -627 promoter polymorphism and PSC.

• Boberg, Kirsten Muri; Schrumpf, Erik; Bergquist, A.; Broome, U.; Pares, A. & Remotti, H. [Show all 9 contributors for this article] (2000). Cholangiocarcinoma in primary sclerosing cholangitis: k-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. Journal of Hepatology. ISSN 0168-8278. 32, p. 374–380.
• Bjøro, Kristian; Höckerstedt, K.; Ericzon, Bo-Göran; Frimann, S.; Hjortrup, A. & Keiding, S. [Show all 7 contributors for this article] (2000). Liver transplantation in patients over 60 years of age. Transplant International. ISSN 0934-0874. 13, p. 165–170.
• Boberg, Kirsten Muri; Brosstad, Frank Roger; Egeland, Thore; Egge, Tor Schatvedt & Schrumpf, Erik (1999). Is a prolonged bleeding time associated with an increased risk of hemorrhage after liver biopsy? Thrombosis and Haemostasis. ISSN 0340-6245. 81, p. 378–81.
• Spurkland, Anne; Saarinen, S.; Boberg, Kirsten Muri; Mitchell, S.A.; Broome, U. & Caballeria, L. [Show all 16 contributors for this article] (1999). HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens. ISSN 0001-2815. 53, p. 459–469.
• Giercksky, Karl-Erik; Boberg, Kirsten Muri; Farstad, Inger Nina; Halvorsen, Sigrun & Schrumpf, Erik (1999). Severe liver failure in exertional heat stroke. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 34, p. 824–827.
• Bjøro, Kristian; Frimann, S.; Höckerstedt, K.; Kirkegaard, P.; Keiding, S. & Schrumpf, Erik [Show all 12 contributors for this article] (1999). Liver transplantations in the Nordic Countries, 1982-9:Changes of indications and improving results. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 34, p. 714–722.
• Søreide, Odd; Husberg, Bo; Bjøro, Kristian & Schrumpf, Erik (1999). Levertransplantasjon - utvikling og erfaringer. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 22, p. 3310–3314.
• Alvarez, J.F.; Berg, P.A.; Bianchi, F.B.; Bianchi, L.; Burroghs, A.K. & Concado, E.L. [Show all 16 contributors for this article] (1999). International autoimmune hepatitis group* report: update on criteria for diagnosis of autoimmune hepatitis. Journal of Hepatology. ISSN 0168-8278. 31, p. 929–938.
• Schrumpf, Erik; Søreide, Odd & Aabakken, Lars (1999). Present situation and future strategy. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 34.

View all works in Cristin

• Benum, E; Haave, Per; Ibsen, Hilde; Schiøtz, Aina & Schrumpf, Erik (2003). Den mangfoldige velferden. Festskrift til Anne-Lise Seip 70 år. Gyldendal Akademisk. ISBN 82-05-32639-8. 315 p.

View all works in Cristin

• Kummen, Martin; Holm, Kristian; Anmarkrud, Jarl Andreas; Vesterhus, Mette; Høivik, Marte & Trøseid, Marius [Show all 12 contributors for this article] (2015). O082 : THE GUT MICROBIOTA IN PRIMARY SCLEROSING CHOLANGITIS DIFFERS FROM THAT OF HEALTHY CONTROLS AND ULCERATIVE COLITIS PATIENTS WITHOUT BILIARY DISEASE.
• Naess, Sigrid; Anmarkrud, Jarl Andreas; Björnsson, Einar; Al Mamari, Said; Juran, Brian D. & Lazaridis, Konstantios N [Show all 13 contributors for this article] (2012). HLA associations in small-duct compared with large-duct primary sclerosing cholangitis. Hepatology. ISSN 0270-9139. 56, p. 1134A–1134A.
• Tjønnfjord, Geir Erland; Schrumpf, Erik & Tierens, Anne (2009). HIGH PREVALENCE OF CLONAL B-CELL DISEASE IN PATIENTS WITH LGL-LEUKEMIA. Haematologica. ISSN 0390-6078. 94, p. 599–599.
• Boberg, Kirsten Muri; Lohse, AW; Hennes, EM; Dienes, HP; Heathcote, EJ & Chapman, RW [Show all 7 contributors for this article] (2009). ASSESSMENT OF 479 PATIENTS WITH AUTOIMMUNE LIVER DISEASES ACCORDING TO THE IAIHG SCORING SYSTEM FOR AUTOIMMUNE HEPATITIS DOES NOT SUPPORT THE CONTENTION OF OVERLAP SYNDROMES AS SEPARATE DIAGNOSTIC ENTITIES. Hepatology. ISSN 0270-9139. 50(4), p. 1009A–1009A.
• Schrumpf, Erik & Bjøro, Kristian (2008). Timing of liver transplantation in PSC. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 43, p. 31–31.
• Melum, Espen; Karlsen, TH; Bergquist, A; Schrumpf, Erik & Boberg, Kirsten Muri (2008). An interleukin-6 (IL-6) receptor polymorphism affecting serum levels of IL-6 does not increase the risk of cholangiocarcinoma in primary sclerosing cholangitis. American Journal of Gastroenterology. ISSN 0002-9270. 103, p. 1045–1045.
• Wiencke, Kristine; Karlsen, TH; Boberg, Kirsten Muri; Harbo, Hanne Flinstad; Lie, Benedicte Alexandra & Thorsby, Erik [Show all 8 contributors for this article] (2005). Association to the HLA-DR6 haplotype in PSC: Additional effects in the HLA class I/extended class I region. Journal of Hepatology. ISSN 0168-8278. 42.
• Berstad, Audun Elnæs; Smith, Hans-Jørgen; Aasen, Steinar; Aabakken, Lars; Boberg, Kirsten Muri & Schrumpf, Erik (2005). Accuracy and interobserver variability of MR cholangiography in the diagnosiss of primary sclerosing cholangitis.
• Berstad, Audun Elnæs; Smith, Hans-Jørgen; Aasen, Steinar; Aabakken, Lars; Boberg, Kirsten Muri & Schrumpf, Erik (2005). Can magnetic resonance cholangiography replace endoscopic retrograde cholangiography in the diagnosis of primary sclerosing cholangitis?
• Schrumpf, Erik & Boberg, Kirsten Muri (2002). Endoscopic treatment for primary sclerosing cholangitis ? Journal of Hepatology. ISSN 0168-8278. 36, p. 278–79.
• Bjørnsson, E.; Boberg, Kirsten Muri; Schrumpf, Erik; Fleming, K.A. & Chapman, R.W. (2001). Patients with small duct primary sclerosing cholangitis have favorable long term prognosis.
• Boberg, Kirsten Muri; Bergquist, A.; Mitchell, A\S.; Rosina, F.; Broome, U. & Chapman, R.W. [Show all 10 contributors for this article] (2001). Cholangiocarsinoma in primary sclerosing cholangitis is associated with long-standing inflammatory bowel disease. A long-term follow-up of 394 primary sclerosing cholangitis patients.
• Schrumpf, Erik (2001). PSC-state of the art.Invited lecture at UEGW-2001.
• Schrumpf, Erik (2001). Diagnosis and therapy of cholangiocarcinoma. EASL postgraduate conference at UEGW.
• Schrumpf, Erik; Søreide, Odd & Aabakken, Lars (2000). Scandinavian Journal of Gastroenterology: a new millennium. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 35, p. 1–1.
• Bjøro, Kristian; Kirkegaard, P.; Ericzon, Bo-Göran; Schrumpf, Erik; Isoniemi, H. & Söderdahl, G. [Show all 11 contributors for this article] (2000). Liver transplantation in the nordic countries 1990-1999.
• Bjøro, Kristian; Kirkegaard, P.; Ericzon, Bo-Göran; Frimann, S.; Schrumpf, Erik & Isoniemi, H. [Show all 11 contributors for this article] (2000). Is a 3-day limit for highly urgent liver transplantation for fulminant hepatic failure appropriate - or is the diagnosis in some cases incorrect?
• Boberg, Kirsten Muri; Mitchell, S.A.; Broome, U.; Pares, A.; Rosina, F. & Bergquist, A. [Show all 10 contributors for this article] (2000). Natural history of primary sclerosing cholangitis. A longterm follow-up study of 394 european primary sclerosing cholangitis patients.
• Schrumpf, Erik & Boberg, Kirsten Muri (2000). Primary sclerosing cholangitis: an important hepatobiliary disease.
• Schrumpf, Erik; Smith, Hans-Jørgen & Clausen, Ole Petter Fraas (2000). Benigne lesjoner i leveren.
• Bjøro, Kristian; Schrumpf, Erik; Bjøro, Trine; Wiencke, Kristine; Brandsæter, Bjørn Jardar & Godang, Kristin [Show all 7 contributors for this article] (2000). Secondary osteoporosis after liver transplantation.
• Wiencke, Kristine; Spurkland, Anne; Schrumpf, Erik & Boberg, Kirsten Muri (2000). MICA and MICB polymorphisms in primary sclerosing cholangitis.
• Bjøro, Kristian; Olson, R. Brandser; Broome, U.; Hockerstedt, K. & Schrumpf, Erik (1999). Liver transplantation for primary sclerosing cholangitis.
• Bjøro, Kristian; Höckerstedt, K.; Ericzon, Bo-Göran & Schrumpf, Erik (1999). Liver transplantation in patients above 60 years of age.
• Bjøro, Kristian; Keiding, S.; Frimann, S. & Schrumpf, Erik (1999). Outcome of patients listed for liver transplantation in the nordic countries 1990-1998.

View all works in Cristin